ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Pfizer's Coming for AbbVie's Market Share. ... (now that Humira is seeing competition from generics as a result of going over the patent cliff in the U.S. this year).

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.

This was the stock's third consecutive day of losses.

This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have ...

Lawmakers in Congress busily marking up bills on pharmacy middlemen this week might want to pay heed to AbbVie’sABBV-0.77%decrease; red down pointing triangle latest earnings results. Investors ...

Revenue at North Chicago-based AbbVie dove by nearly 10% during the first few months of this year — a drop that comes as its bestselling drug Humira faces competition for the first time in the U ...